123 related articles for article (PubMed ID: 9853978)
1. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia.
Facciolà G; Avenoso A; Spina E; Perucca E
Ther Drug Monit; 1998 Dec; 20(6):628-30. PubMed ID: 9853978
[TBL] [Abstract][Full Text] [Related]
2. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders.
Facciolà G; Avenoso A; Scordo MG; Madia AG; Ventimiglia A; Perucca E; Spina E
Ther Drug Monit; 1999 Jun; 21(3):341-5. PubMed ID: 10365650
[TBL] [Abstract][Full Text] [Related]
3. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
[TBL] [Abstract][Full Text] [Related]
4. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics.
Lane HY; Chang YC; Chang WH; Lin SK; Tseng YT; Jann MW
J Clin Psychiatry; 1999 Jan; 60(1):36-40. PubMed ID: 10074876
[TBL] [Abstract][Full Text] [Related]
5. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia.
Guitton C; Abbar M; Kinowski JM; Chabrand P; Bressolle F
J Clin Psychopharmacol; 1998 Dec; 18(6):470-6. PubMed ID: 9864080
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients.
González-Esquivel DF; Castro N; Ramírez-Bermúdez J; Custodio V; Rojas-Tomé S; Castro-Román R; Jung-Cook H
Arzneimittelforschung; 2011; 61(6):335-9. PubMed ID: 21827043
[TBL] [Abstract][Full Text] [Related]
8. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.
Spina E; Avenoso A; Facciolà G; Fabrazzo M; Monteleone P; Maj M; Perucca E; Caputi AP
Int Clin Psychopharmacol; 1998 May; 13(3):141-5. PubMed ID: 9690983
[TBL] [Abstract][Full Text] [Related]
9. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia.
Guitton C; Kinowski JM; Abbar M; Chabrand P; Bressolle F
J Clin Pharmacol; 1999 Jul; 39(7):721-8. PubMed ID: 10392327
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.
Akamine Y; Sugawara-Kikuchi Y; Uno T; Shimizu T; Miura M
Ann Clin Biochem; 2017 Nov; 54(6):677-685. PubMed ID: 27932669
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.
Li LJ; Shang DW; Li WB; Guo W; Wang XP; Ren YP; Li AN; Fu PX; Ji SM; Lu W; Wang CY
Acta Pharmacol Sin; 2012 Nov; 33(11):1409-16. PubMed ID: 22820910
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid.
Li Z; Lee SH; Jeong HJ; Kang HE
Xenobiotica; 2021 Mar; 51(3):324-334. PubMed ID: 33185134
[TBL] [Abstract][Full Text] [Related]
13. Variability of the in vivo metabolism of clozapine.
Raedler TJ; Hinkelmann K; Wiedemann K
Clin Neuropharmacol; 2008; 31(6):347-52. PubMed ID: 19050412
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline.
Spina E; Avenoso A; Salemi M; Facciolá G; Scordo MG; Ancione M; Madia A
Pharmacopsychiatry; 2000 Nov; 33(6):213-7. PubMed ID: 11147928
[TBL] [Abstract][Full Text] [Related]
16. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients.
Hermida J; Paz E; Tutor JC
Ther Drug Monit; 2008 Feb; 30(1):41-5. PubMed ID: 18223461
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients.
Aravagiri M; Marder SR
J Pharm Biomed Anal; 2001 Sep; 26(2):301-11. PubMed ID: 11470207
[TBL] [Abstract][Full Text] [Related]
18. Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients.
Menkes DB; Glue P; Gale C; Lam F; Hung CT; Hung N
EBioMedicine; 2018 Jan; 27():134-137. PubMed ID: 29254680
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia.
Olmos I; Ibarra M; Vázquez M; Maldonado C; Fagiolino P; Giachetto G
Biomed Res Int; 2019; 2019():3163502. PubMed ID: 30956977
[TBL] [Abstract][Full Text] [Related]
20. Clozapine: more than 900 mg/day may be needed.
Maccall C; Billcliff N; Igbrude W; Natynczuk S; Spencer EP; Flanagan RJ
J Psychopharmacol; 2009 Mar; 23(2):206-10. PubMed ID: 18515467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
